Short Bowel Syndrome Market Size, Share, Industry Trends and Forecast to 2033
This report provides a comprehensive analysis of the Short Bowel Syndrome market, including market size, trends, segmentations, and forecasts from 2023 to 2033. It aims to deliver insights into the industry dynamics, regional performance, and key players shaping this market.
| Metric | Value |
|---|---|
| Study Period | 2023 - 2033 |
| 2023 Market Size | $5.60 Billion |
| CAGR (2023-2033) | 5.8% |
| 2033 Market Size | $9.97 Billion |
| Top Companies | Takeda Pharmaceutical Company, Nestlé Health Science, Baxter International, Boehringer Ingelheim, AbbVie Inc. |
| Last Modified Date | 15 Nov 2024 |
Short Bowel Syndrome Market Report (2023 - 2033)
Short Bowel Syndrome Market Overview
What is the Market Size & CAGR of Short Bowel Syndrome market in 2023 and 2033?
Short Bowel Syndrome Industry Analysis
Short Bowel Syndrome Market Segmentation and Scope
Request a custom research report for industry.
Short Bowel Syndrome Market Analysis Report by Region
Europe Short Bowel Syndrome Market Report:
In Europe, the market for Short Bowel Syndrome is expected to increase from $1.59 billion in 2023 to around $2.82 billion by 2033. Factors contributing to this growth include an aging population, increased healthcare investments, and a rise in the prevalence of digestive diseases. European nations are also focusing on bolstering healthcare access and implementing effective treatment protocols.Asia Pacific Short Bowel Syndrome Market Report:
In the Asia Pacific region, the Short Bowel Syndrome market is projected to grow from $1.17 billion in 2023 to approximately $2.08 billion by 2033. The growth is attributed to increasing awareness of gastrointestinal disorders and improvements in healthcare infrastructure, allowing better access to vital treatments. Notable investments in research and development are aimed at creating innovative solutions tailored to the unique demographics of this region.North America Short Bowel Syndrome Market Report:
North America accounts for a significant share of the SBS market, with anticipated growth from $1.95 billion in 2023 to approximately $3.47 billion by 2033. This growth trajectory is largely influenced by robust healthcare systems, highly developed R&D frameworks, and increasing incidences of intestinal disorders. The introduction of specialized therapies approved by regulatory bodies further supports this growth trend.South America Short Bowel Syndrome Market Report:
The South American SBS market is expected to exhibit growth from $0.29 billion in 2023 to around $0.51 billion by 2033. Boosted by rising healthcare access and improvements in nutritional guidelines, the region is progressively addressing the needs associated with SBS. Awareness campaigns and healthcare reforms are essential drivers fostering market expansion.Middle East & Africa Short Bowel Syndrome Market Report:
The Middle East and Africa market is projected to grow from $0.61 billion in 2023 to $1.09 billion by 2033. Economic advancements along with increased healthcare initiatives are facilitating better diagnosis and treatment of SBS. Collaboration between local healthcare providers and international firms is expected to enhance the development and availability of SBS care in the region.Request a custom research report for industry.
Short Bowel Syndrome Market Analysis By Treatment Type
Global Short Bowel Syndrome Market, By Treatment Type Market Analysis (2023 - 2033)
The treatment type segment of the SBS market is dominated by Nutritional Support, which commands a market size of $3.65 billion in 2023 and is expected to reach $6.50 billion by 2033, comprising 65.19% of market share. The Pharmacological Therapy segment holds a market size of $1.38 billion in 2023 and $2.45 billion by 2033, maintaining 24.59% of market share. Additionally, Surgical Options make up the smallest segment with a market size of $0.57 billion in 2023, projected to grow to $1.02 billion by 2033, representing a 10.22% share.
Short Bowel Syndrome Market Analysis By Route Of Administration
Global Short Bowel Syndrome Market, By Route of Administration Market Analysis (2023 - 2033)
When classified by route of administration, the oral route emerges as significant, projected to grow from $3.65 billion in 2023 to $6.50 billion by 2033, maintaining a share of 65.19%. The parenteral route exhibits market sizes of $1.38 billion in 2023, increasing to $2.45 billion by 2033, accounting for 24.59% of overall market share. The enteral administration holds $0.57 billion in 2023 and is estimated to reach $1.02 billion by 2033, comprising 10.22% share within the segment.
Short Bowel Syndrome Market Analysis By Age Group
Global Short Bowel Syndrome Market, By Age Group Market Analysis (2023 - 2033)
Analyzing by age group, pediatric patients are forecasted to dominate with a market size of $3.65 billion in 2023 and anticipated growth to $6.50 billion by 2033, representing 65.19% of market share. Adult patients measure $1.38 billion in 2023, expected to increase to $2.45 billion by 2033, making up 24.59%. Geriatric individuals have a market size of $0.57 billion in 2023, projected to reach $1.02 billion by 2033, constituting a 10.22% share.
Short Bowel Syndrome Market Analysis By End User
Global Short Bowel Syndrome Market, By End-User Market Analysis (2023 - 2033)
Within the end-user segment, hospitals are the leading sector, boasting a market size of $3.65 billion in 2023, expanding to $6.50 billion by 2033 with a consistent share of 65.19%. Home care services hold $1.38 billion in 2023, expected to rise to $2.45 billion by 2033, accounting for 24.59%, while specialty clinics capture $0.57 billion in 2023 with projections up to $1.02 billion by 2033, making up 10.22%.
Short Bowel Syndrome Market Trends and Future Forecast
Request a custom research report for industry.
Global Market Leaders and Top Companies in Short Bowel Syndrome Industry
Takeda Pharmaceutical Company:
Takeda focuses on innovative gastroenterology therapies, including treatments for Short Bowel Syndrome, emphasizing research in conditions that impact intestinal function.Nestlé Health Science:
Nestlé Health Science develops nutritional solutions targeting SBS management, providing advanced enteral and parenteral nutrition products for patients.Baxter International:
Baxter International specializes in medical devices and therapies, with a significant offering in parenteral solutions for patients with SBS.Boehringer Ingelheim:
Boehringer operates in the pharmaceutical sector, focusing on treatment advancements that aid those suffering from Short Bowel Syndrome.AbbVie Inc.:
AbbVie invests heavily in biopharmaceutical research, delivering therapies that positively influence the lives of patients with intestinal diseases.We're grateful to work with incredible clients.
